Cutaneous Lymphoma at Injection Sites: Pathological, Immunophenotypical, and Molecular Characterization in 17 Cats

P. Roccabianca, G. Avallone, A. Rodriguez, L. Crippa, E. Lepri, C. Giudice, M. Caniatti, Peter F Moore, Verena K Affolter

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Feline primary cutaneous lymphomas (FPCLs) account for 0.2% to 3% of all lymphomas in cats and are more frequently dermal nonepitheliotropic small T-cell tumors. Emergence of FPCL seems unrelated to feline leukemia virus (FeLV) serological positivity or to skin inflammation. A total of 17 cutaneous lymphomas with a history of vaccine injection at the site of tumor development were selected from 47 FPCLs. Clinical presentation, histology, immunophenotype, FeLV p27 and gp70 expression, and clonality were assessed. A majority of male (12/17), domestic short-haired (13/17) cats with a mean age of 11.3 years was reported. Postinjection time of development ranged from 15 days to approximately 9 years in 5 cats. At diagnosis, 11 of 17 cats had no evidence of internal disease. Lymphomas developed in interscapular (8/17), thoracic (8/17), and flank (1/17) cutaneous regions; lacked epitheliotropism; and were characterized by necrosis (16/17), angiocentricity (13/17), angioinvasion (9/17), angiodestruction (8/17), and peripheral inflammation composed of lymphoid aggregates (14/17). FeLV gp70 and/or p27 proteins were expressed in 10 of 17 tumors. By means of World Health Organization classification, immunophenotype, and clonality, the lesions were categorized as large B-cell lymphoma (11/17), anaplastic large T-cell lymphoma (3/17), natural killer cell–like (1/17) lymphoma, or peripheral T-cell lymphoma (1/17). Lineage remained uncertain in 1 case. Cutaneous lymphomas at injection sites (CLIS) shared some clinical and pathological features with feline injection site sarcomas and with lymphomas developing in the setting of subacute to chronic inflammation reported in human beings. Persistent inflammation induced by the injection and by reactivation of FeLV expression may have contributed to emergence of CLIS.

Original languageEnglish (US)
Pages (from-to)823-832
Number of pages10
JournalVeterinary Pathology
Volume53
Issue number4
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

injection site
lymphoma
Lymphoma
Cats
cats
Skin
Injections
Feline Leukemia Virus
Felidae
Feline leukemia virus
Inflammation
inflammation
T-lymphocytes
neoplasms
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Neoplasms
T-Cell Lymphoma
B-Cell Lymphoma
injection

Keywords

  • cat
  • clonality
  • FeLV
  • immunohistochemistry
  • injection
  • lymphoma
  • molecular biology
  • skin
  • vaccination

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Cutaneous Lymphoma at Injection Sites : Pathological, Immunophenotypical, and Molecular Characterization in 17 Cats. / Roccabianca, P.; Avallone, G.; Rodriguez, A.; Crippa, L.; Lepri, E.; Giudice, C.; Caniatti, M.; Moore, Peter F; Affolter, Verena K.

In: Veterinary Pathology, Vol. 53, No. 4, 01.07.2016, p. 823-832.

Research output: Contribution to journalArticle

Roccabianca, P. ; Avallone, G. ; Rodriguez, A. ; Crippa, L. ; Lepri, E. ; Giudice, C. ; Caniatti, M. ; Moore, Peter F ; Affolter, Verena K. / Cutaneous Lymphoma at Injection Sites : Pathological, Immunophenotypical, and Molecular Characterization in 17 Cats. In: Veterinary Pathology. 2016 ; Vol. 53, No. 4. pp. 823-832.
@article{d1fed548bdac4e8d9b16dddf33f3af1e,
title = "Cutaneous Lymphoma at Injection Sites: Pathological, Immunophenotypical, and Molecular Characterization in 17 Cats",
abstract = "Feline primary cutaneous lymphomas (FPCLs) account for 0.2{\%} to 3{\%} of all lymphomas in cats and are more frequently dermal nonepitheliotropic small T-cell tumors. Emergence of FPCL seems unrelated to feline leukemia virus (FeLV) serological positivity or to skin inflammation. A total of 17 cutaneous lymphomas with a history of vaccine injection at the site of tumor development were selected from 47 FPCLs. Clinical presentation, histology, immunophenotype, FeLV p27 and gp70 expression, and clonality were assessed. A majority of male (12/17), domestic short-haired (13/17) cats with a mean age of 11.3 years was reported. Postinjection time of development ranged from 15 days to approximately 9 years in 5 cats. At diagnosis, 11 of 17 cats had no evidence of internal disease. Lymphomas developed in interscapular (8/17), thoracic (8/17), and flank (1/17) cutaneous regions; lacked epitheliotropism; and were characterized by necrosis (16/17), angiocentricity (13/17), angioinvasion (9/17), angiodestruction (8/17), and peripheral inflammation composed of lymphoid aggregates (14/17). FeLV gp70 and/or p27 proteins were expressed in 10 of 17 tumors. By means of World Health Organization classification, immunophenotype, and clonality, the lesions were categorized as large B-cell lymphoma (11/17), anaplastic large T-cell lymphoma (3/17), natural killer cell–like (1/17) lymphoma, or peripheral T-cell lymphoma (1/17). Lineage remained uncertain in 1 case. Cutaneous lymphomas at injection sites (CLIS) shared some clinical and pathological features with feline injection site sarcomas and with lymphomas developing in the setting of subacute to chronic inflammation reported in human beings. Persistent inflammation induced by the injection and by reactivation of FeLV expression may have contributed to emergence of CLIS.",
keywords = "cat, clonality, FeLV, immunohistochemistry, injection, lymphoma, molecular biology, skin, vaccination",
author = "P. Roccabianca and G. Avallone and A. Rodriguez and L. Crippa and E. Lepri and C. Giudice and M. Caniatti and Moore, {Peter F} and Affolter, {Verena K}",
year = "2016",
month = "7",
day = "1",
doi = "10.1177/0300985815623620",
language = "English (US)",
volume = "53",
pages = "823--832",
journal = "Veterinary Pathology",
issn = "0300-9858",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Cutaneous Lymphoma at Injection Sites

T2 - Pathological, Immunophenotypical, and Molecular Characterization in 17 Cats

AU - Roccabianca, P.

AU - Avallone, G.

AU - Rodriguez, A.

AU - Crippa, L.

AU - Lepri, E.

AU - Giudice, C.

AU - Caniatti, M.

AU - Moore, Peter F

AU - Affolter, Verena K

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Feline primary cutaneous lymphomas (FPCLs) account for 0.2% to 3% of all lymphomas in cats and are more frequently dermal nonepitheliotropic small T-cell tumors. Emergence of FPCL seems unrelated to feline leukemia virus (FeLV) serological positivity or to skin inflammation. A total of 17 cutaneous lymphomas with a history of vaccine injection at the site of tumor development were selected from 47 FPCLs. Clinical presentation, histology, immunophenotype, FeLV p27 and gp70 expression, and clonality were assessed. A majority of male (12/17), domestic short-haired (13/17) cats with a mean age of 11.3 years was reported. Postinjection time of development ranged from 15 days to approximately 9 years in 5 cats. At diagnosis, 11 of 17 cats had no evidence of internal disease. Lymphomas developed in interscapular (8/17), thoracic (8/17), and flank (1/17) cutaneous regions; lacked epitheliotropism; and were characterized by necrosis (16/17), angiocentricity (13/17), angioinvasion (9/17), angiodestruction (8/17), and peripheral inflammation composed of lymphoid aggregates (14/17). FeLV gp70 and/or p27 proteins were expressed in 10 of 17 tumors. By means of World Health Organization classification, immunophenotype, and clonality, the lesions were categorized as large B-cell lymphoma (11/17), anaplastic large T-cell lymphoma (3/17), natural killer cell–like (1/17) lymphoma, or peripheral T-cell lymphoma (1/17). Lineage remained uncertain in 1 case. Cutaneous lymphomas at injection sites (CLIS) shared some clinical and pathological features with feline injection site sarcomas and with lymphomas developing in the setting of subacute to chronic inflammation reported in human beings. Persistent inflammation induced by the injection and by reactivation of FeLV expression may have contributed to emergence of CLIS.

AB - Feline primary cutaneous lymphomas (FPCLs) account for 0.2% to 3% of all lymphomas in cats and are more frequently dermal nonepitheliotropic small T-cell tumors. Emergence of FPCL seems unrelated to feline leukemia virus (FeLV) serological positivity or to skin inflammation. A total of 17 cutaneous lymphomas with a history of vaccine injection at the site of tumor development were selected from 47 FPCLs. Clinical presentation, histology, immunophenotype, FeLV p27 and gp70 expression, and clonality were assessed. A majority of male (12/17), domestic short-haired (13/17) cats with a mean age of 11.3 years was reported. Postinjection time of development ranged from 15 days to approximately 9 years in 5 cats. At diagnosis, 11 of 17 cats had no evidence of internal disease. Lymphomas developed in interscapular (8/17), thoracic (8/17), and flank (1/17) cutaneous regions; lacked epitheliotropism; and were characterized by necrosis (16/17), angiocentricity (13/17), angioinvasion (9/17), angiodestruction (8/17), and peripheral inflammation composed of lymphoid aggregates (14/17). FeLV gp70 and/or p27 proteins were expressed in 10 of 17 tumors. By means of World Health Organization classification, immunophenotype, and clonality, the lesions were categorized as large B-cell lymphoma (11/17), anaplastic large T-cell lymphoma (3/17), natural killer cell–like (1/17) lymphoma, or peripheral T-cell lymphoma (1/17). Lineage remained uncertain in 1 case. Cutaneous lymphomas at injection sites (CLIS) shared some clinical and pathological features with feline injection site sarcomas and with lymphomas developing in the setting of subacute to chronic inflammation reported in human beings. Persistent inflammation induced by the injection and by reactivation of FeLV expression may have contributed to emergence of CLIS.

KW - cat

KW - clonality

KW - FeLV

KW - immunohistochemistry

KW - injection

KW - lymphoma

KW - molecular biology

KW - skin

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=84975065651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975065651&partnerID=8YFLogxK

U2 - 10.1177/0300985815623620

DO - 10.1177/0300985815623620

M3 - Article

C2 - 26933095

AN - SCOPUS:84975065651

VL - 53

SP - 823

EP - 832

JO - Veterinary Pathology

JF - Veterinary Pathology

SN - 0300-9858

IS - 4

ER -